These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Phase II study of vindesine in patients with non-small cell lung cancer.
    Author: Fujita J, Saijo N, Eguchi K, Shinkai T, Tominaga K, Sasaki Y, Futami H, Sakurai M, Ishihara J, Takahashi H.
    Journal: Jpn J Cancer Res; 1985 Sep; 76(9):902-5. PubMed ID: 2997097.
    Abstract:
    A phase II study of vindesine (VDS) was carried out in 21 patients with non-small cell lung cancer (NSCLC). There were 13 and 8 patients with and without prior chemotherapy, respectively. VDS was administered at a weekly iv dose of 3 mg/m2. Partial response was observed in two of 15 adenocarcinomas and one of 2 adenosquamous cell carcinomas, and the overall response rate was 14.3% (3/21). Myelosuppression, especially leukopenia, was the most common dose-limiting side effect. Neurotoxicity was also a common side effect but the degree was mild. It was concluded that VDS at a dose of 3 mg/m2 every week seems to be active against NSCLC.
    [Abstract] [Full Text] [Related] [New Search]